{"id":10138,"date":"2024-01-05T22:27:00","date_gmt":"2024-01-05T14:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10138"},"modified":"2024-10-28T22:31:17","modified_gmt":"2024-10-28T14:31:17","slug":"shanghai-pharmaceuticals-subsidiary-reprimanded-again-for-monopolisitic-pricing-of-polymyxin-b-sulfate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10138","title":{"rendered":"Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate"},"content":{"rendered":"\n

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607<\/a>; SHA: 601607<\/a>), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to reduce the online procurement price of the drug from RMB 270 to RMB 123 and ensure supply security.<\/p>\n\n\n\n

SHP No.1 Bio’s exclusive version of polymyxin B sulfate is utilized in the treatment of Gram-negative bacterial infections, including urinary tract, meninges, and bloodstream infections caused by Pseudomonas aeruginosa.<\/p>\n\n\n\n

In the first half of 2023, the State Anti-Monopoly Bureau (SAMR) found that SHP No.1 Bio had conspired with three other companies\u2014Wuhan Healcare Pharma, Wuhan Kede Pharma, and Hubei Minkang Pharma\u2014to inflate the cost of drug raw materials by hundreds of times. This led to an unreasonable price increase of polymyxin sulfate B injection to over RMB 2,303 per dose, significantly higher than in overseas markets. The drug generated RMB 4 billion in sales within five years. Following the first interview by the National Healthcare Security Administration in June 2023, which requested a price reduction to RMB 270 from RMB 2,303-2,918 per piece, the company was fined RMB 1.219 billion by Shanghai\u2019s AMR bureau in December 2023.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[890,891,196],"class_list":["post-10138","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals"],"yoast_head":"\nShanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to reduce the online procurement price of the drug from RMB 270 to RMB 123 and ensure supply security.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-05T14:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T14:31:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate\",\"datePublished\":\"2024-01-05T14:27:00+00:00\",\"dateModified\":\"2024-10-28T14:31:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10138#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10138\",\"name\":\"Shanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-01-05T14:27:00+00:00\",\"dateModified\":\"2024-10-28T14:31:17+00:00\",\"description\":\"The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to reduce the online procurement price of the drug from RMB 270 to RMB 123 and ensure supply security.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10138\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate - Insight, China's Pharmaceutical Industry","description":"The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to reduce the online procurement price of the drug from RMB 270 to RMB 123 and ensure supply security.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10138","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10138","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-01-05T14:27:00+00:00","article_modified_time":"2024-10-28T14:31:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate","datePublished":"2024-01-05T14:27:00+00:00","dateModified":"2024-10-28T14:31:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10138"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10138#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10138","url":"https:\/\/flcube.com\/?p=10138","name":"Shanghai Pharmaceuticals' Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-01-05T14:27:00+00:00","dateModified":"2024-10-28T14:31:17+00:00","description":"The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to reduce the online procurement price of the drug from RMB 270 to RMB 123 and ensure supply security.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10138"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10138\/revisions"}],"predecessor-version":[{"id":10139,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10138\/revisions\/10139"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}